Wells Fargo raised the firm’s price target on Sabra Health Care to $16 from $14 and keeps an Equal Weight rating on the shares. The firm offered updated thoughts on Healthcare REITs following Q2 earnings from the group, saying it is maintains a favorable view on Healthcare as a weaker jobs report and lower end consumer point to easing labor costs, which should drive better metrics. The firm is also encouraged the equity market is open for investment capital, the analyst tells investors in the sector note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA:
- Sabra Healthcare REIT Releases Supplemental Investor Package
- Sabra Health Care ups FY24 normalized FFO view to $1.41-$1.44, consensus $1.40
- Sabra Health Care reports Q2 normalized AFFO 36c, consensus 35c
- SBRA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Skilled nursing facilities’ outlook likely improved by Chevron ruling, says RBC